John Contis1, Panagis M Lykoudis1, Kallirroi Goula2, Despoina Karandrea2, Agathi Kondi-Pafiti2. 1. 2nd Department of Surgery, Aretaieio University Hospital, National and Kapodistrian University of Athens, Athens, Greece. 2. Department of Pathology, Aretaieio University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Abstract
CONTEXT: Survivin is an antiapoptotic protein with a role in tumorigenesis and suggested prognostic value in several proliferative diseases. AIMS: This study aimed to examine the role of survivin as a prognostic marker in pancreatic adenocarcinoma (PDAC). SETTINGS AND DESIGN: Fifty-one specimens of PDAC were assessed for survivin expression by immunohistochemistry. SUBJECTS AND METHODS: Overall survival and 1-, 3-, and 5-year survival were retrieved retrospectively. STATISTICAL ANALYSIS USED: Bivariate analysis was conducted using Chi-square and Mann-Whitney U tests, while survival analysis was conducted using Kaplan-Meier statistics. RESULTS: Of the 51 assessed cases, 49% were positive for survivin. Survivin expression was significantly correlated 1-year survival and overall survival, particularly in bcl-2 positive cases. CONCLUSIONS: Survivin may be implicated in the bcl-2 and p53 pathways and therefore in the biology of PDAC. Its potential use as a survival predictor and therapeutic target represent a promising field.
CONTEXT: Survivin is an antiapoptotic protein with a role in tumorigenesis and suggested prognostic value in several proliferative diseases. AIMS: This study aimed to examine the role of survivin as a prognostic marker in pancreatic adenocarcinoma (PDAC). SETTINGS AND DESIGN: Fifty-one specimens of PDAC were assessed for survivin expression by immunohistochemistry. SUBJECTS AND METHODS: Overall survival and 1-, 3-, and 5-year survival were retrieved retrospectively. STATISTICAL ANALYSIS USED: Bivariate analysis was conducted using Chi-square and Mann-Whitney U tests, while survival analysis was conducted using Kaplan-Meier statistics. RESULTS: Of the 51 assessed cases, 49% were positive for survivin. Survivin expression was significantly correlated 1-year survival and overall survival, particularly in bcl-2 positive cases. CONCLUSIONS: Survivin may be implicated in the bcl-2 and p53 pathways and therefore in the biology of PDAC. Its potential use as a survival predictor and therapeutic target represent a promising field.